Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/46790
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Boronat, Mauro | en_US |
dc.contributor.author | García-Cantón, César | en_US |
dc.contributor.author | López-Ríos, Laura | en_US |
dc.contributor.author | Quevedo, Virginia | en_US |
dc.contributor.author | Lorenzo, Dionisio L. | en_US |
dc.contributor.author | Batista, Fátima | en_US |
dc.contributor.author | Riaño, Marta | en_US |
dc.contributor.author | Nóvoa, Francisco J. | en_US |
dc.date.accessioned | 2018-11-23T08:13:16Z | - |
dc.date.available | 2018-11-23T08:13:16Z | - |
dc.date.issued | 2014 | en_US |
dc.identifier.issn | 1479-1641 | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/46790 | - |
dc.description.abstract | This study analyses discordance rates between attainment of therapeutic goals for apolipoprotein B100 (apoB) and both low-density lipoprotein-cholesterol (LDL-C) and non-high-density lipoprotein-cholesterol (non-HDL-C) in a sample of 152 patients with type 2 diabetes and chronic kidney disease from Gran Canaria (Spain), using treatment targets recommended by the American Diabetes Association/American College of Cardiology (ADA/ACC), the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) and by a Spanish population-based study. Among subjects with LDL-C levels at therapeutic goal, apoB was above target in 16.3% (ADA/ACC), 6.5% (ESC/EAS) and 39.1% (population-based criteria), and among subjects with non-HDL-C levels at therapeutic goal, apoB was above target in 10.5% (ADA/ACC), 1.2% (ESC/EAS) and 29.6% (population-based criteria). These findings show that clinical management would be very differently altered depending on the criteria used to set treatment targets for apoB. Cut-off points derived from population data identify a greater number of subjects suitable for a more intensive lipid-lowering therapy. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Diabetes and Vascular Disease Research | en_US |
dc.source | Diabetes and Vascular Disease Research [ISSN 1479-1641],v. 11, p. 53-59 | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject | 3205 Medicina interna | en_US |
dc.subject.other | Apolipoprotein B100, | en_US |
dc.subject.other | Low-density lipoprotein–cholesterol | en_US |
dc.subject.other | Non-high-density lipoprotein–cholesterol | en_US |
dc.subject.other | Cardiovascular risk | en_US |
dc.subject.other | Lipid goals | en_US |
dc.subject.other | Type 2 diabetes | en_US |
dc.title | Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease | en_US |
dc.type | info:eu-repo/semantics/Article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1177/1479164113511834 | en_US |
dc.identifier.scopus | 84890453908 | - |
dc.identifier.isi | 000328315700009 | - |
dc.contributor.authorscopusid | 7003952293 | - |
dc.contributor.authorscopusid | 6603127359 | - |
dc.contributor.authorscopusid | 33068166900 | - |
dc.contributor.authorscopusid | 50561862600 | - |
dc.contributor.authorscopusid | 55967938300 | - |
dc.contributor.authorscopusid | 55968288300 | - |
dc.contributor.authorscopusid | 37067926100 | - |
dc.contributor.authorscopusid | 12786120600 | - |
dc.description.lastpage | 59 | en_US |
dc.description.firstpage | 53 | en_US |
dc.relation.volume | 11 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.contributor.daisngid | 673494 | - |
dc.contributor.daisngid | 1915819 | - |
dc.contributor.daisngid | 1964185 | - |
dc.contributor.daisngid | 5112593 | - |
dc.contributor.daisngid | 30519221 | - |
dc.contributor.daisngid | 5867919 | - |
dc.contributor.daisngid | 5257474 | - |
dc.contributor.daisngid | 556390 | - |
dc.description.numberofpages | 7 | en_US |
dc.utils.revision | Sí | en_US |
dc.contributor.wosstandard | WOS:Boronat, M | - |
dc.contributor.wosstandard | WOS:Garcia-Canton, C | - |
dc.contributor.wosstandard | WOS:Lopez-Rios, L | - |
dc.contributor.wosstandard | WOS:Quevedo, V | - |
dc.contributor.wosstandard | WOS:Lorenzo, DL | - |
dc.contributor.wosstandard | WOS:Batista, F | - |
dc.contributor.wosstandard | WOS:Riano, M | - |
dc.contributor.wosstandard | WOS:Novoa, FJ | - |
dc.date.coverdate | Enero 2014 | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.sjr | 1,202 | |
dc.description.jcr | 2,829 | |
dc.description.sjrq | Q1 | |
dc.description.jcrq | Q2 | |
dc.description.scie | SCIE | |
item.grantfulltext | none | - |
item.fulltext | Sin texto completo | - |
crisitem.author.dept | GIR IUIBS: Diabetes y endocrinología aplicada | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.orcid | 0000-0001-8535-8543 | - |
crisitem.author.orcid | 0000-0002-5988-8222 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.fullName | Boronat Cortés, Mauro | - |
crisitem.author.fullName | García Cantón, César | - |
crisitem.author.fullName | Lorenzo Villegas, Dionisio Lorenzo | - |
Appears in Collections: | Artículos |
SCOPUSTM
Citations
3
checked on Nov 3, 2024
WEB OF SCIENCETM
Citations
3
checked on Nov 3, 2024
Page view(s)
37
checked on Feb 25, 2023
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.